Calliditas Therapeutics AB (publ) (NASDAQ:CALT) vs. ASLAN Pharmaceuticals (NASDAQ:ASLN) Head to Head Review

Earnings & Valuation

This table compares ASLAN Pharmaceuticals and Calliditas Therapeutics AB (publ)”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62

Calliditas Therapeutics AB (publ) has higher revenue and earnings than ASLAN Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares ASLAN Pharmaceuticals and Calliditas Therapeutics AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Insider & Institutional Ownership

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Calliditas Therapeutics AB (publ) beats ASLAN Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.